Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?
Options
BORIS DOI
Date of Publication
June 26, 2024
Publication Type
Article
Division/Institute
Contributor
Gómez-Aparicio, María Antonia | |
López-Campos, Fernando | |
Buchser, David | |
Lazo, Antonio | |
Willisch, Patricia | |
Ocanto, Abrahams | |
Sargos, Paul | |
Couñago, Felipe |
Subject(s)
Series
Cancers
ISSN or ISBN (if monograph)
2072-6694
Publisher
MDPI AG
Language
en
Publisher DOI
PubMed ID
39001393
Uncontrolled Keywords
Description
The treatment landscape for metastatic hormone-sensitive prostate cancer continues to evolve, with systemic treatment being the mainstay of current treatment. Prognostic and predictive factors such as tumour volume and disease presentation have been studied to assess responses to different treatments. Intensification and de-escalation strategies arouse great interest, so several trials are being developed to further personalize the therapy in these populations. Is there an optimal sequence and a possible option to de-intensify treatment in selected patients with a favourable profile? This and other goals will be the subject of this review.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content |
|---|